PMID- 37444636
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230718
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 15
IP  - 13
DP  - 2023 Jul 7
TI  - Stereotactic Body Radiation Therapy in Gynecologic Oligometastases: An Effective 
      but Underutilized Approach.
LID - 10.3390/cancers15133526 [doi]
LID - 3526
AB  - Historically, the role of radiation in gynecological metastatic disease involved 
      palliation for pain or bleeding. Stereotactic Body Radiation Therapy (SBRT) has 
      shown survival benefits in oligometastatic disease from varying primary 
      histologies in recent randomized trials. However, gynecologic primary 
      oligometastases have been underrepresented in these trials. Recent studies across 
      gynecological malignancy types have similarly shown favorable outcomes and 
      acceptable toxicities from treating recurrent or oligometastatic gynecologic 
      cancer (ROMGC) patients with definitive radiation therapy. The largest body of 
      literature reported on the use of SBRT in ovarian cancer, which was found to be 
      an effective option, especially in the setting of chemo-resistant disease. 
      Despite the encouraging outcomes using SBRT in oligometastatic gynecologic 
      malignancies, SBRT remains underutilized given the lack of randomized studies 
      studying ROMGC with long term follow-up. While waiting for future prospective 
      trials to establish the role of SBRT as the standard of care in ROMGC patients, 
      this review focuses on reporting the advantages and drawbacks of this technique 
      and examines the current literature to help guide patient centered treatment 
      decisions.
FAU - Sherwani, Zohaib
AU  - Sherwani Z
AUID- ORCID: 0000-0001-7856-3063
AD  - Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers 
      University, New Brunswick, NJ 08901, USA.
FAU - Parikh, Shreel
AU  - Parikh S
AD  - Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers 
      University, New Brunswick, NJ 08901, USA.
FAU - Yegya-Raman, Nikhil
AU  - Yegya-Raman N
AD  - Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 
      19104, USA.
FAU - McKenna, Kelly
AU  - McKenna K
AD  - Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers 
      University, New Brunswick, NJ 08901, USA.
FAU - Deek, Matthew
AU  - Deek M
AD  - Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers 
      University, New Brunswick, NJ 08901, USA.
FAU - Jabbour, Salma
AU  - Jabbour S
AD  - Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers 
      University, New Brunswick, NJ 08901, USA.
FAU - Hathout, Lara
AU  - Hathout L
AUID- ORCID: 0000-0003-3062-9793
AD  - Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers 
      University, New Brunswick, NJ 08901, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230707
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC10340138
OTO - NOTNLM
OT  - cervical cancer
OT  - gynecologic cancer
OT  - oligometastases
OT  - ovarian cancer
OT  - stereotactic body radiation therapy
OT  - uterine cancer
COIS- The authors declare no conflict of interest.
EDAT- 2023/07/14 13:06
MHDA- 2023/07/14 13:07
PMCR- 2023/07/07
CRDT- 2023/07/14 01:06
PHST- 2023/04/14 00:00 [received]
PHST- 2023/07/01 00:00 [revised]
PHST- 2023/07/03 00:00 [accepted]
PHST- 2023/07/14 13:07 [medline]
PHST- 2023/07/14 13:06 [pubmed]
PHST- 2023/07/14 01:06 [entrez]
PHST- 2023/07/07 00:00 [pmc-release]
AID - cancers15133526 [pii]
AID - cancers-15-03526 [pii]
AID - 10.3390/cancers15133526 [doi]
PST - epublish
SO  - Cancers (Basel). 2023 Jul 7;15(13):3526. doi: 10.3390/cancers15133526.